2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12B.16 Effectiveness of Alectinib in ALK Rearrangement NSCLC: Real World Data of Peru

Pdf Summary

The study led by Katia Roque, MD, evaluated the effectiveness of Alectinib in treating non-small cell lung cancer (NSCLC) with ALK rearrangements in a Peruvian context. This condition constitutes approximately 5% of NSCLC cases internationally and 3-5% in Peru. Despite limitations in access to targeted therapy, the introduction of tyrosine kinase inhibitors in 2019 has improved survival rates for this patient group.<br /><br />The retrospective study was conducted on 23 patients treated at the Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru, from 2019-2023. The patients, with an average age of 51, were divided nearly equally by gender and predominantly had adenocarcinoma (87%). Smoking was reported in 26% of the cases, with 17% exposed to wood smoke. Patients also varied in disease presentation, with nearly half experiencing brain metastasis.<br /><br />In terms of response, Alectinib showed an overall response rate (ORR) of 74%, with a clinical benefit rate of 83.3%. At the time of reporting, median progression-free survival (PFS) and median overall survival (OS) were not reached, with 4-year PFS and OS rates at 66.7% and 64.1%, respectively. This indicates a potentially enduring benefit from Alectinib therapy in treating this patient cohort.<br /><br />Adverse effects were primarily hepatotoxic, though severe side effects were rare, necessitating dose reductions in a few cases. Despite challenges, Alectinib has proven effective, notably even among patients with central nervous system metastases, typically difficult to manage. Thus, this study reveals promising real-world outcomes for Alectinib among NSCLC patients in Peru, aligning with global results and underscoring its vital role in treatment protocols.

Asset Subtitle

Rossana Ruiz

Meta Tag

Speaker Rossana Ruiz

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Alectinib

non-small cell lung cancer

NSCLC

ALK rearrangements

Peru

tyrosine kinase inhibitors

brain metastasis

progression-free survival

overall survival

hepatotoxicity